Discovery In Chromosome Replication Process May Prove Valuable In Cancer Diagnosis

April 24, 1997

An international research team has discovered the key protein in an enzyme responsible for lengthening the ends of chromosomes, a surprising finding that potentially could lead to the development of new ways to detect and treat cancer.

Ironically, the protein is nearly identical to the protein responsible for some viral diseases, including HIV, said Thomas Cech, a professor of chemistry and biochemistry at the University of Colorado and a Howard Hughes Medical Institute Investigator. The enzyme in which the protein was found, telomerase, is unusual because it contains a form of genetic material known as RNA.

The researchers showed the newly identified protein in yeast acts as the "catalytic center of telomerase, the heart of the enzyme," which is selectively activated in many cancer cells, said Cech.

The protein type, known as a "reverse transcriptase," also facilitates the onset and spread of HIV and other retroviruses by copying RNA into DNA and inserting it into the chromosome of hosts. Reverse transcriptase proteins also have been known to shuffle genetic information within the cells, he said.

Such proteins had not been thought to have an essential function in normal cells prior to the discovery, reported in the April 25 issue of Science. Co-authors of the study included Cech and Joachim Lingner of CU and HHMI, Tim Hughes and Victoria Lundblad of the Baylor College of Medicine in Houston, and Andrej Shevenko and Matthias Mann of the European Molecular Biology Laboratory in Heidelberg.

"It is a great irony that a protein essential for complete replication of chromosomes has the same detailed shape as the protein responsible for the replication of HIV," said Cech, who shared the 1989 Nobel Prize in chemistry.

Telomerase has been heralded by some as a promising new approach to the diagnosis and treatment of cancer. If current theories regarding its role in human cancer prove accurate, then variants of pharmaceuticals like AZT currently being used to treat AIDS patients may prove useful as anti-cancer agents, Cech said.

Telomerase, which has been shown to be active in about 85 percent of cancer cells, is not found in adjacent, healthy cells, said the researchers. It may be possible to develop a drug that could "turn off" the production of telomerase in cancer cells, causing them to revert to normal activity, the researchers speculated.

In the Science paper, the researchers showed that changing even a single amino acid out of the 884 acids in the enzyme's chain prevented telomerase from working in living yeast cells. Cells carrying a mutant telomerase protein gradually lost DNA from their chromosome ends and ceased growing after about 75 generations.

A University of Colorado patent covering the new discovery has been licensed to Geron Corp. of Menlo Park, Calif., through the University Technology Corp.

"This breakthrough discovery of the only known essential protein component of telomerase in diverse species shows it is very widespread in biology," said Dr. Calvin Harley, Geron's vice president for research. "We think it likely that it will lead to the discovery of the key human protein, which, together with the known essential RNA component, should accelerate the discovery of therapeutics targeting telomerase."

The pathway to the discovery began in 1994, when CU postdoc Joachim Lingner began purifying telomerase from a single-celled pond organism known as Euplotes containing millions of small chromosomes rather than the 46 large ones found in human cells. Although Euplotes had much larger amounts of telomerase per cell, it nevertheless took two years to purify and analyze it with the help of high-tech mass spectrometry work conducted by the Heidelberg team.

A computer search of Genome Project data by the researchers identified a close relative of the gene for the Euplotes telomerase among chromosomes of baker's yeast. The Colorado team learned that Lunblad's Baylor lab in Houston had found the same yeast gene -- one of only four yeast genes known to result in shorter chromosome ends, or telomeres, when mutated.

Finding the yeast gene corresponding to the telomerase protein allowed the researchers to test the hypothesis that the reverse transcriptase action of the protein was essential for chromosome replication. The CU and Baylor groups introduced single amino-acid mutations into the proposed reverse transcriptase structure of the yeast protein.

"These changes obliterated telomerase activity in living cells and in the test tube, providing strong evidence the new protein provides the active center of the telomerase," said Cech.

- 30 -

University of Colorado at Boulder

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to